Literature DB >> 19896317

Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.

Qingyu Zhou1, James M Gallo.   

Abstract

The primary challenge associated with the development of an assay method for the determination of drug concentrations in relatively small amount of mouse plasma and tissue samples is to improve extraction efficiency and detection sensitivity. In this work, a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based method combined with protein precipitation, liquid-liquid extraction and solid-phase extraction techniques was developed for the determination of sunitinib in mouse plasma, brain tumor and normal brain tissue, respectively. The instrument was operated under the multiple reaction monitoring (MRM) mode using electrospray ionization (ESI) in the positive ion mode. A good linear relationship with coefficients of determination >or=0.99 was achieved over the concentration ranges of 1.37-1000ng/mL for plasma and 4.12-1000ng/g for the normal brain and brain tumor. The limits of quantification (LOQs) for sunitinib in mouse plasma, brain tumor and normal brain tissue are 1.37ng/mL, 4.12ng/g and 4.12ng/g, respectively. The reproducibility of the LC-MS/MS method is reliable, with the intra- and inter-day precision being less than 15% and accuracy within +/-15%. The established method was successfully applied to the characterization of sunitinib disposition in the brain and brain tumor as well as its systemic pharmacokinetics in a murine orthotopic glioma model. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896317      PMCID: PMC2814903          DOI: 10.1016/j.jpba.2009.10.006

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  16 in total

1.  Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction.

Authors:  S Barattè; S Sarati; E Frigerio; C A James; C Ye; Q Zhang
Journal:  J Chromatogr A       Date:  2004-01-23       Impact factor: 4.759

2.  Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.

Authors:  Yeping Zhao; Juthamas Sukbuntherng; Lida Antonian
Journal:  J Pharm Biomed Anal       Date:  2004-05-28       Impact factor: 3.935

3.  High-performance liquid chromatographic method for determination of reversible isomers of SU5416.

Authors:  Anand Sistla; Wei-Lien Yang; Narmada Shenoy
Journal:  J Chromatogr A       Date:  2006-02-10       Impact factor: 4.759

Review 4.  Sunitinib: from rational design to clinical efficacy.

Authors:  Laura Q M Chow; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

5.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Authors:  Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert A Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

6.  Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

Authors:  S Patyna; J Haznedar; D Morris; K Freshwater; G Peng; J Sukbuntherng; G Chmielewski; D Matsumoto
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2009-06

7.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Authors:  Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
Journal:  Mol Cancer Ther       Date:  2003-05       Impact factor: 6.261

8.  Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2007-03-07       Impact factor: 3.575

9.  Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

Authors:  Sophie de Boüard; Paulette Herlin; James G Christensen; Edwige Lemoisson; Pascal Gauduchon; Eric Raymond; Jean-Sébastien Guillamo
Journal:  Neuro Oncol       Date:  2007-07-10       Impact factor: 12.300

Review 10.  Molecular basis for sunitinib efficacy and future clinical development.

Authors:  Sandrine Faivre; George Demetri; William Sargent; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

View more
  8 in total

1.  Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

Authors:  B Neyns; J Sadones; C Chaskis; M Dujardin; H Everaert; S Lv; J Duerinck; O Tynninen; N Nupponen; A Michotte; J De Greve
Journal:  J Neurooncol       Date:  2010-09-25       Impact factor: 4.130

2.  Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; James Fisher; William F Elmquist
Journal:  Chromatographia       Date:  2013-12-01       Impact factor: 2.044

3.  Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.

Authors:  S Torok; A Vegvari; M Rezeli; T E Fehniger; J Tovari; S Paku; V Laszlo; B Hegedus; A Rozsas; B Dome; G Marko-Varga
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

4.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

5.  Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Authors:  Qingyu Zhou; Hua Lv; Amin R Mazloom; Huilei Xu; Avi Ma'ayan; James M Gallo
Journal:  J Pharmacol Exp Ther       Date:  2012-08-06       Impact factor: 4.030

6.  A biodegradable perivascular wrap for controlled, local and directed drug delivery.

Authors:  William G Sanders; Paul C Hogrebe; David W Grainger; Alfred K Cheung; Christi M Terry
Journal:  J Control Release       Date:  2012-04-27       Impact factor: 9.776

7.  Sunitinib treatment for multiple brain metastases from jejunal gastrointestinal stromal tumor: case report.

Authors:  Hayato Takeuchi; Hiroshi Koike; Tomoaki Fujita; Hitoshi Tsujino; Yoshihiro Iwamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-20       Impact factor: 1.742

8.  MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.

Authors:  C Marcela Diaz-Montero; Frances J Mao; John Barnard; Yvonne Parker; Maryam Zamanian-Daryoush; John J Pink; James H Finke; Brian I Rini; Daniel J Lindner
Journal:  Br J Cancer       Date:  2016-08-25       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.